Appeals court denies HHS request to pause lower court order blocking federal agency restructuring plans that would cut 10,000 ...

AstraZeneca and Handa Pharmaceuticals have agreed to pay a combined $51.4 million to resolve a class action lawsuit that ...

Summit Therapeutics' ivonescimab shows 48% PFS benefit but misses OS endpoint in Phase 3 lung cancer trial; drug's regulatory ...

Biopharma faces uncertainty in H2 2025 amid policy concerns and market challenges, with key healthcare conferences and ...

Summit Therapeutics’ mixed results for its potential competitor to Merck’s Keytruda left an important question unanswered: ...

Adding Pfizer’s BRAF inhibitor Braftovi to a cocktail of cancer drugs cut the risk of death for certain colorectal cancer ...

Youngblood has left Bristol Myers Squibb to join Acadia Pharmaceuticals as SVP of its rare disease franchise. She had a ...

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

The US Supreme Court will continue deciding whether to take up a pivotal case on state PBM regulation after the federal ...

Astellas is the latest large pharmaceutical company to ink a deal with a Chinese biotech, paying $130 million upfront for a ...

Since Bernard Ravina's medical training in neurology in the '90s, there have been few new therapies that treat a movement ...

The companies said Thursday that they voluntarily withdrew the accelerated approval request for patritumab deruxtecan in ...